• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the June 18, 2010 Meeting of the Advisory Committee for Reproductive Health Drugs

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

 

FDA

 

Disclaimer

 

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

  

FDA Briefing Information, Flibanserin, for the June 18, 2010 Meeting of the Advisory Committee for Reproductive Health Drugs (PDF – 2.20MB)

 

 

Boehringer Ingelheim

 

Disclaimer

 

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

Boehringer Ingelheim Briefing Information, Flibanserin, for the June 18, 2010 Meeting of the Advisory Committee for Reproductive Health Drugs (PDF – 1.23MB)